WORLD J SURG 润色咨询

WORLD JOURNAL OF SURGERY

出版年份:1977 年文章数:7736 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:6.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2023-10-22 ms8000000504841700 来自山东省

    偏重的研究方向:外科;普外科;胃肠
    经验分享:文章接收很快,从投到接收三个月

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2022-04-03 独行er

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:外科
    经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。
    但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.
    应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀

    6

    展开6条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2023-05-31 drop13 来自上海

    审稿速度:6.0 | 投稿命中率:75.0
    经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2022-11-05 1def03bbm67(暂无匿称)

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:临床与病理结合;临床
    经验分享:2022.6.11 Awaiting Admin Processing
    2022.6.18 Under review
    2022.6.20 Under Review
    2022.8.11 Awaiting EIC Decision
    2022.8.16 Minor Revision
    2022.9.13 Resubmit
    2022.9.13 Awaiting Admin Processing
    2022.9.23 Under Review
    2022.11.1 Awaiting EIC Decision
    2022.11.5 Accept

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2022-06-28 独行er

    最新 IF 3.07,好悬

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2022-05-06 ms5000001369153496

    偏重的研究方向:文献计量学
    经验分享:Awaiting Admin Processing 11天了什么情况啊

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2020-03-09 winterlegend

    审稿速度:2.0
    经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2021-12-29 桑晒麦拉

    上传文章有什么要求?

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2021-12-28 学医的彭于晏

    如何判断两种药物之间是协同作用还是相加作用?

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2164169, encodeId=38ac21641697b, content=偏重的研究方向:外科;普外科;胃肠<br>经验分享:文章接收很快,从投到接收三个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2be8562513, createdName=ms8000000504841700, createdTime=Sun Oct 22 09:29:21 CST 2023, time=2023-10-22, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1208316, encodeId=cde51208316a4, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:外科<br>经验分享:前后2月余,小修一次,今天收到接收函。今年应该还在3分以上。<br>但是,接收函里有这么一句:has been accepted in its current form for publication in the World Journal of Surgery contingent upon a Crosscheck scan. After acceptance, all WJS material is put through a computer search comparing the new material with all previously published scientific work. We will contact you if any significant "overlap" is demonstrated.<br>应该是接收后还要查重。我自己查了一下,发现和自己以前的一篇文章重复率4%(捂脸ing),都是方法学部分里的句子。好担心呀。大家有没有相同的经历呀<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Sun Apr 03 10:34:07 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140170, encodeId=3bb321401e014, content=审稿速度:6.0 | 投稿命中率:75.0<br>经验分享:杂志审稿挺快的,主要是我自己有点拖。就是accept之后已经两个月了多,也不知道如何了。因为接收信里说还要查重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad82999046, createdName=drop13, createdTime=Wed May 31 21:19:12 CST 2023, time=2023-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098768, encodeId=66d72098e6870, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:临床与病理结合;临床<br>经验分享:2022.6.11 Awaiting Admin Processing<br>2022.6.18 Under review<br>2022.6.20 Under Review<br>2022.8.11 Awaiting EIC Decision<br>2022.8.16 Minor Revision<br>2022.9.13 Resubmit<br>2022.9.13 Awaiting Admin Processing<br>2022.9.23 Under Review<br>2022.11.1 Awaiting EIC Decision<br>2022.11.5 Accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14131732842, createdName=1def03bbm67(暂无匿称), createdTime=Sat Nov 05 22:21:03 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229258, encodeId=9e5e12292586d, content=最新 IF 3.07,好悬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5cd32801854, createdName=独行er, createdTime=Tue Jun 28 20:49:10 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217458, encodeId=d194121e45816, content=偏重的研究方向:文献计量学<br>经验分享:Awaiting Admin Processing 11天了什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a7e5696898, createdName=ms5000001369153496, createdTime=Fri May 06 22:36:26 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586210, encodeId=6cff586210ce, content=审稿速度:2.0<br>经验分享:2019.12.15 Awaiting Admin Processing 2019.12.22 under review 2020.2.11 Awaiting EIC Decision 2020.2.16 Reject & Resubmit 2020.2.20 Resubmit 2020.2.20 Awaiting Admin Processing 2020.2.20 Under Review 2020.3.1 Awaiting EIC Decision 2020.3.1 Accept 2020.3.1 Awaiting Production Checklist 2020.3.3 Awaiting Assignment to Batch 2020.3.3 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231202/f5d54a76129e4a5880bb7e96cd04be64/2b678d90720348f68ac1a3082a7047cc.jpg, createdBy=1fd31636241, createdName=winterlegend, createdTime=Mon Mar 09 00:00:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099573, encodeId=c9b110995e3bc, content=上传文章有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099574, encodeId=eca610995e436, content=如何判断两种药物之间是协同作用还是相加作用?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971359, encodeId=6ba09e135971, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:外科<br>经验分享:接受率18%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cf75514792, createdName=ms6000001952465217, createdTime=Sun Jun 06 19:21:57 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2021-06-06 ms6000001952465217

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:外科
    经验分享:接受率18%

    0

共56条页码: 1/6页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分